Board of Directors
Dr Thierry Sulpice, Ph.D
Chairman, CEO/CSO, Founder
Dr Thierry Sulpice has served as Chief Executive / Scientific Officer since incorporationof Cardiomedex in 2011. He is also Chairman and CEO/CSO of Physiogenex and his expertise covers the physiopathology and pharmacology of vascular/heart diseases, type 2 diabetes, dyslipidemia, liver and kidneys disorders.
Prior to managing both CROs Thierry was head of the in vivo pharmacology team at Sanofi-Aventis where he led drug discovery optimization and preclinical development for projects targeting the cardio-metabolic syndrome. During his 9-year tenure at Sanofi-Aventis, he was particularly involved in the cannabinoid CB1 receptor program and managed many animal studies which aimed to determine the potential efficacy of new drug targets.
Thierry earned his PhD Degree in “Pharmacology and cellular physiology of cardiac cells” at the University of Grenoble, France. In addition, Dr. Sulpice led basic research on the physiopathology of the diabetic heart at Orsay University, France.
Dr Caroline Dubroca, PhD
Director,Scientific Operations and Research Development
Dr Caroline Dubroca has served as an expert in cardiovascular diseases since October 2011 and has been instrumental in developing Cardiomedex services. She drives research development and projects management. Caroline has over 15 years of experience in pharmacology within both academic research and private companies. Being involved in drug discovery and development process she gained industry know-how and a thorough knowledge of cardiovascular issues.
Her majors focus are heart failure, myocardial infarction, cardiac hypertrophy and vascular function and she is highly experienced in study protocol development, small animal surgery, physiological and pharmacological functional evaluations.
She earned her PhD Degree in “Biology and Pharmacology of haemostasis and vessels” at Paris VII University, France. She led her post-doctoral research on cardiac stem cells biology in Pharmacology and Therapeutics Unit at Brussels, Belgium.
Dr Rana Assaly, PharmD, PhD
Director, Scientific and Business Development
Dr Rana Assaly has joined Cardiomedex since March 2023 to drive scientific and business development and contribute to delivering first-in-class preclinical efficacy and safety studies. Rana has over 15 years of experience in pharmacology within both academic research and private companies and has been involved in drug discovery and development process.
Prior to joining, Rana was Chief Operating Officer at Pelvipharm where she led preclinical efficacy projects and served as an expert in vascular and women’s health pharmacology to internal and external stakeholders. Her work was presented in international meetings and published in scientific journals.
Since 2008, Rana has been actively involved in basic research on cardiovascular physiopathology and served as assistant professor at Paris Saclay University, France and continues to be engaged as an invited speaker.
Rana also worked in the marketing and sales department at Novartis in the United Arab of Emirates.
She earned her Pharmacy diploma at the Lebanese American University, Lebanon and led her PhD Degree in “Experimental and Clinical Pharmacology” at Paris XI/Paris Saclay University, France.
SCIENTIFIC ADVISORY BOARD
Pr Atul Pathak, MD, PhD
Co-Founder, Chair of Scientific Advisory Board
Pr Atul Pathak is a Cardiologist and Pharmacologist. He is currently Chief of Cardiology at “Centre Hospitalier Princesse Grace”,Monaco.
After graduating from RTWH Aachen (Germany) and Toulouse University (France) he received his medical doctorate from Toulouse University. He especially focused on the field of cardiovascular autonomic physiology and pharmacology during his internship / residency at the Cleveland Clinic (USA) and University of Brussels (Belgium). He has also been visiting Professor to the Baker IDI Heart and Diabetes Institute (Melbourne, Australia) where he initiated the renal denervation program.
Pr Pathak serves as Vice President of the French Society for Hypertension and President of the European Society for Patient Care. He has been awarded by the European and French Society of Cardiology, and the British Pharmacological Society. He is also on numerous editorial boards and member of the American Society for Heart Failure.
Pr Jean-Michel Senard, MD, PhD
Co-Founder, Member of Scientific Advisory Board
Pr Jean-Michel Senard, is a Pharmacologist specialized in Cardiovascular Systems and Neurosciences. Pr Senard serves as the medical head of the Unit of Clinical Neuropharmacology and of the Laboratory of Autonomic Nervous System at Toulouse Hospital. He heads also the “Molecular and Clinical Determinants of cardiac architecture” team at the French national medical research institute (INSERM, U1048, Toulouse).
His research focuses on heart architecture with special emphasis on the identification of molecular determinants of cardiomyocyte morphology / cardiac tissue organization, and pharmacology of cardiac cell surface GPCR.
Pr Senard obtained his MD and PhD in Pharmacology in Toulouse, France. He is a member of the French Society of Pharmacology and Therapeutics, the French society of Cardiology and Hypertension and the European Federation of Autonomic Societies (EFAS).
CONTACT US FOR MORE INFORMATION